Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.73 |
| ▸ | KRAS | P01116 | 2/20 | 0.70 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.67 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | F3 | P13726 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | P4HB | P07237 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634204 | 1.00 | MCL1 (0.73) | MCL1KRASMKNK2NPC1CXCL12 | |
| SCHEMBL26794146 | 0.88 | MKNK2 (0.79) | MCL1KRASMKNK2CXCL12TNFRSF1A | |
| SCHEMBL25208931 | 0.87 | MCL1 (0.77) | MCL1KRASNPC1CXCL12TNFRSF1A | |
| SCHEMBL25193998 | 0.87 | MCL1 (0.77) | MCL1KRASNPC1CXCL12TNFRSF1A | |
| SCHEMBL13018517 | 0.82 | KRAS (1.00) | MCL1KRASCXCL12TNFRSF1AKDM4E | |
| SCHEMBL615818 | 0.82 | KRAS (1.00) | MCL1KRASCXCL12TNFRSF1AKDM4E | |
| SCHEMBL25206860 | 0.82 | MKNK2 (1.00) | MKNK2NPC1CXCL12TNFRSF1APTPN1 | |
| SCHEMBL30384137 | 0.82 | MKNK2 (1.00) | MKNK2NPC1CXCL12TNFRSF1APTPN1 | |
| SCHEMBL30928252 | 0.81 | GAA (0.80) | TNFRSF1AKDM4EGAA | |
| SCHEMBL30928261 | 0.81 | GAA (0.80) | TNFRSF1AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | MCL1 3646/4885KRAS 3351/4885MKNK2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.